bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
262 hedge funds and large institutions have $2.73B invested in bluebird bio in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 93 increasing their positions, 86 reducing their positions, and 57 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 86
0.14% less ownership
Funds ownership: 7.39% → 7.24% (-0.14%)
7% less call options, than puts
Call options by funds: $45.9M | Put options by funds: $49.1M
5% less funds holding
Funds holding: 275 → 262 (-13)
19% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 57
20% less capital invested
Capital invested by funds: $3.41B → $2.73B (-$680M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$41.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27.8M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$21.3M |
| 4 |
JP Morgan Chase
New York
|
+$20.9M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$91.2M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$33.5M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$30.2M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$21.6M |
| 5 |
ACA
Anchor Capital Advisors
Boston,
Massachusetts
|
-$21.4M |
BLUE Hedge Fund Activity: Q4 2020 in Review
262 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2020, worth a combined $2.73B — down 20% from $3.41B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of BLUE and 46 opened new positions — a net loss of 11 holders — while 86 trimmed existing stakes and 93 added.
The largest buyer was Credit Suisse, adding an estimated $41.4M. The largest seller was Wellington Management Group, cutting an estimated $91.2M.
- 262 institutional investors held bluebird bio (BLUE) as of Q4 2020, down from 275 in Q3 2020.
- Funds reported $2.73B of bluebird bio stock for Q4 2020, down 20% quarter-over-quarter.
- 46 funds opened new bluebird bio positions in Q4 2020 and 57 closed out, a net change of -11 holders.
- The largest bluebird bio buyer in Q4 2020 was Credit Suisse, an estimated $41.4M added.
- The largest bluebird bio seller in Q4 2020 was Wellington Management Group, an estimated $91.2M sold.
Based on aggregated 13F filings for Q4 2020.